MasterSwitch Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

MasterSwitch Bio is an early-stage, private biotech focused on creating controllable cell therapies for oncology and immunology. The company is in a stealth or pre-launch phase, as indicated by its 'Coming Soon' website, suggesting active platform development and likely securing of early-stage financing. Operating from the major biotech hub of Cambridge, it is positioned to leverage local talent and capital to advance its switchable cell therapy platform, which seeks to mitigate risks like cytokine release syndrome and on-target, off-tumor toxicity. The company's success will hinge on translating its preclinical platform into a viable clinical pipeline.

OncologyImmunology

Technology Platform

Platform for developing switchable cell therapies and immunotherapies, enabling external control over the activation and activity of therapeutic cells to enhance safety and efficacy.

Opportunities

The large and growing market for cell therapies, particularly in solid tumors, presents a major opportunity.

A successful switchable platform could address critical safety limitations, enable outpatient administration, and be broadly applicable across multiple cancer types and potentially autoimmune diseases.

Risk Factors

High technical risk that the switchable platform may not function with sufficient precision or potency in humans.

Intense competition from other companies developing controllable cell therapies, and the inherent financing and regulatory risks associated with an early-stage biotech developing a novel combination product.

Competitive Landscape

The field of controllable cell therapies is competitive and includes both private biotechs (e.g., with small molecule-switchable systems) and large pharmaceutical companies investing in next-generation CAR-T platforms. Differentiation will depend on the simplicity, reliability, and clinical performance of MasterSwitch's specific switch technology.

More companies in United States →